Cellectar Biosciences Inc (STU:NV4)

€ 0.6 -0.58 (-49.15%) Market Cap: 50.05 Mil Enterprise Value: 30.97 Mil PE Ratio: 0 PB Ratio: 17.13 GF Score: 38/100

Q3 2024 Cellectar Biosciences Inc Earnings Call Transcript
Nov 18, 2024

€1.73 (+1.17%)

Earnings
Q2 2024 Cellectar Biosciences Inc Earnings Call Transcript
Aug 13, 2024

€1.77 (+5.36%)

Earnings
Q1 2024 Cellectar Biosciences Inc Earnings Call Transcript
May 14, 2024

€2.86 (+5.15%)

Earnings
Q4 2023 Cellectar Biosciences Inc Earnings Call Transcript
Mar 27, 2024

€3.42 (-3.39%)

Earnings
Cellectar Biosciences Inc KOL Call Transcript
Jan 19, 2024
Cellectar Biosciences Inc at EBD Group Biotech Showcase Transcript
Jan 09, 2024
Cellectar Biosciences Inc Top-line Data Call Transcript
Jan 08, 2024
Q3 2023 Cellectar Biosciences Inc Earnings Call Transcript
Nov 02, 2023

€2.16 (-0.92%)

Earnings
Cellectar Biosciences Inc Annual Shareholders Meeting Transcript
Jun 23, 2023
Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 14, 2023
Cellectar Biosciences Inc at ROTH Conference Transcript
Mar 13, 2023
Cellectar Biosciences Inc at Oppenheimer Fall Healthcare Life Sciences & MedTech Summit (Virtual) Transcript
Sep 20, 2021
Cellectar Biosciences Inc at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Cellectar Biosciences Inc at Next Generation Targeted Cancer Therapies - The Cellectar Story! Transcript
Oct 16, 2020

Cellectar Biosciences Inc at Oppenheimer Healthcare Conference (Virtual) Transcript

Mar 14, 2023 / 02:00PM GMT

Release Date Price: €1.46 (+2.82%)

Transcript 10-K/A8-K10-K

Jeff Jones

Oppenheimer & Co. - Analyst

Good morning, and welcome to day two of Oppenheimer's 33rd Annual Healthcare Conference. I'm Jeff Jones, senior analyst here on the biotechnology team, and I wanted to welcome Jim Caruso, CEO of Cellectar Biosciences.

Jim, I will hand it off to you. Why don't you take this away?

Jim Caruso

Cellectar Biosciences, Inc. - President, CEO, & Director

All right. Terrific, Jeff, thank you very much. And thank you once again for the opportunity to participate in your conference, always appreciate it.

As you may or may not know, the obligatory forward-looking statement is always present in any presentation. Cellectar Biosciences, for those of you that are unfamiliar with the story, has really focused on the research and development of oncology therapeutics, both rare pediatric as well as adult malignancies.

The foundation of our focus is our phospholipid ether or PLE delivery platform. And we have demonstrated the capacity to deliver a wide variety of classes of oncology therapeutics

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.